JP2010531846A5 - - Google Patents

Download PDF

Info

Publication number
JP2010531846A5
JP2010531846A5 JP2010513952A JP2010513952A JP2010531846A5 JP 2010531846 A5 JP2010531846 A5 JP 2010531846A5 JP 2010513952 A JP2010513952 A JP 2010513952A JP 2010513952 A JP2010513952 A JP 2010513952A JP 2010531846 A5 JP2010531846 A5 JP 2010531846A5
Authority
JP
Japan
Prior art keywords
antibody
binding fragment
fragment
antagonist
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010513952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010531846A (ja
JP5554703B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/058339 external-priority patent/WO2009000929A2/en
Publication of JP2010531846A publication Critical patent/JP2010531846A/ja
Publication of JP2010531846A5 publication Critical patent/JP2010531846A5/ja
Application granted granted Critical
Publication of JP5554703B2 publication Critical patent/JP5554703B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010513952A 2007-06-28 2008-06-27 自己免疫疾患の治療のための組成物および方法 Active JP5554703B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IE20070468 2007-06-28
IE2007/0468 2007-06-28
US3837208P 2008-03-20 2008-03-20
US61/038,372 2008-03-20
IE20080209 2008-03-20
IE2008/0209 2008-03-20
PCT/EP2008/058339 WO2009000929A2 (en) 2007-06-28 2008-06-27 Composition and method for treatment of autoimmune disease

Publications (3)

Publication Number Publication Date
JP2010531846A JP2010531846A (ja) 2010-09-30
JP2010531846A5 true JP2010531846A5 (cg-RX-API-DMAC7.html) 2011-08-04
JP5554703B2 JP5554703B2 (ja) 2014-07-23

Family

ID=39758798

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010513952A Active JP5554703B2 (ja) 2007-06-28 2008-06-27 自己免疫疾患の治療のための組成物および方法

Country Status (7)

Country Link
US (1) US8580255B2 (cg-RX-API-DMAC7.html)
EP (1) EP2170392A2 (cg-RX-API-DMAC7.html)
JP (1) JP5554703B2 (cg-RX-API-DMAC7.html)
CN (1) CN101808662A (cg-RX-API-DMAC7.html)
AU (1) AU2008267151B2 (cg-RX-API-DMAC7.html)
CA (1) CA2691784C (cg-RX-API-DMAC7.html)
WO (1) WO2009000929A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167129B1 (en) * 2007-07-05 2015-06-17 Opsona Therapeutics Limited Compounds and methods for the treatment of renal disease
US9981018B2 (en) 2010-06-08 2018-05-29 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
WO2011156451A2 (en) * 2010-06-08 2011-12-15 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
US9890202B2 (en) * 2010-07-19 2018-02-13 Yeda Research And Development Co. Ltd. Peptides based on the transmembrane domain of a toll-like receptor (TLR) for treatment of TLR-mediated diseases
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
AU2012223366B2 (en) 2011-03-03 2017-02-23 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
HK1220699A1 (zh) * 2013-03-15 2017-05-12 University Of Florida Research Foundation, Inc. 治疗神经退行性蛋白质病的化合物
WO2016154586A1 (en) 2015-03-26 2016-09-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Toll-like receptor 2 ligands and methods of making and using thereof
CN107847657A (zh) * 2015-06-15 2018-03-27 生命治疗有限公司 用于诱导抗炎反应的组合物和方法
ES3023183T3 (en) 2018-01-02 2025-05-30 Univ Rush Medical Center Compositions and methods for treating neurological and other disorders
WO2020011869A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting tlr2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927332D0 (en) * 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
US7388080B2 (en) * 2003-08-20 2008-06-17 University Of Massachusetts Selective inhibition of toll-like receptor-2
US8623353B1 (en) 2003-09-23 2014-01-07 Technische Universitat Munchen TLR2 antagonistic antibody and use thereof
JP2007514648A (ja) * 2003-10-24 2007-06-07 エーザイ株式会社 Toll−likereceptor2に関連する疾患及び状態を治療するための化合物及び方法
WO2005079419A2 (en) 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
DE602005021694D1 (de) * 2004-12-10 2010-07-15 Novimmune Sa Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung
CN101218254A (zh) * 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
US20100143336A1 (en) * 2007-04-26 2010-06-10 Opsona Therapeutics Limited Toll-like receptor binding epitope and compositions for binding thereto

Similar Documents

Publication Publication Date Title
ES2514495T3 (es) Anticuerpos humanizados modificados anti-interleucina-18
HRP20191341T1 (hr) Protutijela koja vežu ljudski cgrp receptor
Shaw et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling
JP2020039360A5 (cg-RX-API-DMAC7.html)
TWI687440B (zh) St2l拮抗劑及使用方法
FI3592384T3 (fi) Vasta-aineita, jotka spesifisesti sitoutuvat ihmisen IL-1R7:ään
US10618957B2 (en) Antibody molecules which bind CD79
JP2022031635A5 (cg-RX-API-DMAC7.html)
HRP20191342T1 (hr) Anti-phf-tau antitijela i njihove upotrebe
JP2019214582A (ja) Cd3/cd38 t細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法
JP2012516158A5 (cg-RX-API-DMAC7.html)
JP2012501670A5 (cg-RX-API-DMAC7.html)
JP2012501669A5 (cg-RX-API-DMAC7.html)
HRP20171080T1 (hr) Protutijela s modificiranim affinitetom za fcrn koja potiču uklanjanje antigena
JP2017522043A5 (cg-RX-API-DMAC7.html)
JP2012531922A5 (ja) Toll様受容体2へのヒト化抗体またはその抗原結合部位
EA201001467A1 (ru) Моноклональное антитело и способ его использования
JP2015501291A5 (cg-RX-API-DMAC7.html)
JP6009431B2 (ja) アフィニティー精製の方法
EA034647B1 (ru) Молекулы антител, связывающие cd22
EP3169705A2 (en) Molecules with specificity for cd79 and cd22
CA2526546A1 (en) Methods for producing antibodies
RU2011145428A (ru) АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
HRP20221260T1 (hr) Humanizirana i kimerna monoklonska protutijela za cd47
HRP20200918T1 (hr) Modificirane mutirane fuzijske molekule interferonskog antitijela